Expression and methylation status of the FHIT gene in acute myeloid leukemia and myelodysplastic syndrome

To clarify the role of fragile histidine triad (FHIT) in hematological malignancies, we examined the methylation status and the expression level of the FHIT gene in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) cells in comparison with the methylation of the p15INK4B gene. The FHIT methylation was found in 13 of 94 (13.8%) AML and 22 of 40 (55.0%) MDS cases, but not in normal mononuclear cells (MNCs). Both the frequency and density of methylation increased in the advanced-stages MDS and the relapsed AML cases. Although FHIT and p15INK4B methylations were not correlated in MDS and AML, increased FHIT methylation at the relapse in AML was associated with p15INK4B methylation. The median expression level in AML was significantly higher than in normal MNCs, although the median expression level in those with methylation was significantly lower than in those without methylation. Furthermore, the methylation level at relapse was significantly higher than at diagnosis in AML. These results suggested that FHIT methylation was accumulated through the disease progression of MDS and AML, and the role of the FHIT gene as a tumor suppressor seemed different in AML and MDS.

[1]  C. Croce,et al.  Role of FHIT in Human Cancer , 1999 .

[2]  M. Rugge,et al.  Loss of FHIT expression in gastric carcinoma. , 1998, Cancer research.

[3]  C. Hallas,et al.  Loss of FHIT expression in acute lymphoblastic leukemia. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  Y. Pekarsky,et al.  FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. , 1999, Cancer research.

[5]  Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. , 1997 .

[6]  C. Croce,et al.  Structure and expression of the human FHIT gene in normal and tumor cells. , 1997, Cancer research.

[7]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[8]  C. Croce,et al.  FHIT in human cancer. , 1998, Advances in cancer research.

[9]  C. Croce,et al.  Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies. , 2003, Molecular cancer research : MCR.

[10]  M. Verma,et al.  Epigenetics in cancer: implications for early detection and prevention. , 2002, The Lancet. Oncology.

[11]  T. Naoe,et al.  Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. , 2004, Blood.

[12]  T. Kamijo,et al.  Dynamic DNA methylation change in the CpG island region of p15 during human myeloid development. , 2001, The Journal of clinical investigation.

[13]  C. Croce,et al.  The FHIT Gene, Spanning the Chromosome 3p14.2 Fragile Site and Renal Carcinoma–Associated t(3;8) Breakpoint, Is Abnormal in Digestive Tract Cancers , 1996, Cell.

[14]  J. Chang,et al.  Aberrant FHIT transcripts in acute myeloid leukaemia , 1997, British journal of haematology.

[15]  M. Melhem,et al.  FHIT protein expression and its relation to apoptosis, tumor histologic grade and prognosis in colorectal adenocarcinoma: An immunohistochemical and image analysis study , 2004, Clinical & Experimental Metastasis.

[16]  C. Croce,et al.  Significance of FHIT expression in chronic myelogenous leukemia. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  M. Tschan,et al.  Aberrant FHIT mRNA transcripts are present in malignant and normal haematopoiesis, but absence of FHIT protein is restricted to leukaemia , 1999, Oncogene.

[18]  H. Drexler.  Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia–lymphoma cells , 1998, Leukemia.

[19]  Y. Pekarsky,et al.  FHIT: from gene discovery to cancer treatment and prevention. , 2002, The Lancet. Oncology.

[20]  K. Huebner,et al.  Differential susceptibility of renal carcinoma cell lines to tumor suppression by exogenous Fhit expression. , 2000, Cancer research.

[21]  K. Miyagawa,et al.  Decreased or Altered Expression of the FHIT Gene in Human Leukemias , 1997, Stem cells.

[22]  Y. Pommier,et al.  Loss of heterozygosity of nucleotide excision repair factors in sporadic ovarian, colon and lung carcinomas: implication for their roles of carcinogenesis in human solid tumors. , 2001, Cancer letters.

[23]  C. Croce,et al.  FHIT gene alterations in head and neck squamous cell carcinomas. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[24]  B. Quesnel,et al.  Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. , 1998, Blood.

[25]  J. Minna,et al.  Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. , 1999, Cancer research.

[26]  F. Kaye,et al.  Protein expression and functional analysis of the FHIT gene in human tumor cells. , 1998, Journal of the National Cancer Institute.

[27]  T. Taki,et al.  Pattern of FHIT gene expression in normal and leukaemic cells , 1999, International journal of cancer.

[28]  L. D. Barnes,et al.  Replacement of Fhit in cancer cells suppresses tumorigenicity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Minna,et al.  5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. , 2001, Cancer research.

[30]  Yao-chang Chen,et al.  Methylation of the p15INK4B gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation , 2001, British journal of haematology.

[31]  Li Yu,et al.  [DNA methylation and cancer]. , 2005, Zhonghua nei ke za zhi.

[32]  R. Aguiar,et al.  Aberrant transcripts of the FHIT gene are expressed in normal and leukaemic haemopoietic cells. , 1998, British Journal of Cancer.

[33]  T. Naoe,et al.  B‐cell precursors differentiated from cord blood CD34+ cells are more immature than those derived from granulocyte colony‐stimulating factor‐mobilized peripheral blood CD34+ cells , 2001, Immunology.

[34]  Ichiro Mori,et al.  Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.